Want to see ENTX full AI Analyst Report?
ENTX Stock Chart & Stats
$3.47
-$0.08(-3.76%)
At close: 4:00 PM EDT
$3.47
-$0.08(-3.76%)
Day’s Range― - ―
52-Week Range$0.91 - $4.20
Previous CloseN/A
Volume163.47K
Average Volume (3M)3.41M
Market Cap
$521.50M
Enterprise Value$71.29
Total Cash (Recent Filing)$11.31M
Total Debt (Recent Filing)$425.00K
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Nov 05, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding173,834,270
10 Day Avg. Volume295,506
30 Day Avg. Volume3,412,100
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)6.84
Price to Sales (P/S)2133.59
P/FCF Ratio-11.98
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside159.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$54.58M
Bulls Say, Bears Say
Bulls Say
Strong Funding RunwayThe sizable financing supports EB613 Phase 3 execution, advances EB612 and other pipeline programs, and reduces near-term dependence on additional capital while the company works toward regulatory milestones.
Phase 3 Regulatory And Clinical ReadinessFDA agreement on a registrational design and supportive pharmacology data reduce development uncertainty and provide a clearer path for EB613 to address demand for an oral anabolic osteoporosis therapy.
Experienced Clinical LeadershipAdding a senior leader with global clinical, regulatory and commercialization experience strengthens execution capacity as Entera transitions EB613 into late-stage development and manages a broader peptide pipeline.
Bears Say
No Meaningful Commercial RevenueEntera remains a clinical-stage business without an approved commercial product, so revenue visibility is limited and future value depends heavily on successful development, regulatory approval and eventual partnerships.
Persistent Operating Cash BurnHeavy recurring cash outflows show that operations are not self-financing. Continued clinical investment will require substantial capital, leaving the company exposed to financing needs if programs take longer or cost more than planned.
Meaningful Future Dilution CapacityThe enlarged share authorization and recent equity financing provide flexibility to fund development, but they also create significant capacity for future issuance that could dilute existing shareholders as losses continue.
Entera Bio News
ENTX FAQ
What was Entera Bio Ltd’s price range in the past 12 months?
Entera Bio Ltd lowest stock price was $0.91 and its highest was $4.20 in the past 12 months.
What is Entera Bio Ltd’s market cap?
Entera Bio Ltd’s market cap is $521.50M.
When is Entera Bio Ltd’s upcoming earnings report date?
Entera Bio Ltd’s upcoming earnings report date is Nov 05, 2026 which is in 59 days.
How were Entera Bio Ltd’s earnings last quarter?
Entera Bio Ltd released its earnings results on Aug 07, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.08 by -$0.06.
Is Entera Bio Ltd overvalued?
According to Wall Street analysts Entera Bio Ltd’s price is currently Undervalued.
Does Entera Bio Ltd pay dividends?
Entera Bio Ltd does not currently pay dividends.
What is Entera Bio Ltd’s EPS estimate?
Entera Bio Ltd’s EPS estimate is -0.08.
How many shares outstanding does Entera Bio Ltd have?
Entera Bio Ltd has 173,834,270 shares outstanding.
What happened to Entera Bio Ltd’s price movement after its last earnings report?
Entera Bio Ltd reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.08. Following the earnings report the stock price went up 5.923%.
Which hedge fund is a major shareholder of Entera Bio Ltd?
Currently, no hedge funds are holding shares in ENTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Entera Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (159.37% Upside)
$9.00 (159.37% Upside)
Blogger Sentiment
Bullish
ENTX Sentiment 100%
Sector Average 60%
Sector Average 60%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 11.4%
Last 30 Days ▲ 11.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.88%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-0.95%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Entera Bio Ltd
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
ENTX Stock 12 Month Forecast
Average Price Target
$9.00
▲(159.37% Upside)
Technical Analysis
Ownership Overview
1.34% Insiders
0.01% Mutual Funds
5.50% Other Institutional Investors
93.15% Public Companies and
Individual Investors